A possible suppressive role of galectin-3 in upregulated osteoclastogenesis accompanying adjuvant-induced arthritis in rats

Laboratory Investigation

Volumn 89, Issue 1, 2009, Pages 26-37

  Li, Yin Ji ^a   Kukita, Akiko ^b   Teramachi, Junpei ^a   Nagata, Kengo ^a   Wu, Zhou ^a   Akamine, Akifumi ^a   Kukita, Toshio ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

Adjuvant arthritis; Bone destruction; Galectin 3; NFATc1; RANKL; Rheumatoid arthritis

Indexed keywords

GALECTIN 3; GALECTIN 7; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN NFATC1; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKLE; ARTICLE; BONE DESTRUCTION; CELL CULTURE; CONTROLLED STUDY; DISEASE SEVERITY; DISTAL TIBIA FRACTURE; DRUG EFFECT; DRUG INHIBITION; FEMALE; GRANULOCYTE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE MARROW CELLS; BONE RESORPTION; CARBOHYDRATE METABOLISM; CELL DIFFERENTIATION; CELL DIVISION; CELLS, CULTURED; FEMALE; GALECTIN 3; INJECTIONS, INTRA-ARTICULAR; MALE; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; RANK LIGAND; RATS; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; STEM CELLS; TIBIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58149134020     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.111     Document Type: Article

References (54)

1. Hsu DK, Liu FT. Regulation of cellular homeostasis by galectins. Glycoconj J 2004;19:507-515.
2. Liu FT. Molecular biology of IgE-binding protein, IgE-binding factors, and IgE receptors. Crit Rev Immunol 1990;10:289-306.
3. Liu FT, Hsu DK, Zuberi RI, et al. Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol 1995;147:1016-1028.
4. Truong MJ, Gruart V, Kusnierz JP, et al. Human neutrophils express immunoglobulin E (IgE)-binding proteins (Mac-2/epsilon BP) of the S-type lectin family: role in IgE-dependent activation. J Exp Med 1993;177:243-248.
5. Truong MJ, Gruart V, Liu FT, et al. IgE-binding molecules (Mac-2/epsilon BP) expressed by human eosinophils. Implication in IgE-dependent eosinophil cytotoxicity. Eur J Immunol 1993;23:3230-3235.
6. Hrdlicková-Cela E, Plzák J, Smetana Jr K, et al. Detection of galectin-3 in tear fluid at disease states and immunohistochemical and lectin histochemical analysis in human corneal and conjunctival epithelium. Br J Ophthalmol 2001;85:1336-1340.
7. Nachtigal M, Al-Assaad Z, Mayer EP, et al. Galectin-3 expression in human atherosclerotic lesions. Am J Pathol 1998;152:1199-1208.
8. Zuberi RI, Hsu DK, Kalayci O, et al. Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am J Pathol 2004;165:2045-2053.
9. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-310.
10. Gough A, Sambrook P, Devlin J, et al. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998;25:1282-1289.
11. Gravallese EM, Harada Y, Wang JT, et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998;152:943-951.
12. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342.
13. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
14. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-309.
15. Takayanagi H, Iizuka H, Juji T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259-269.
16. Toh K, Kukita T, Wu Z, et al. Possible involvement of MIP-1alpha in the recruitment of osteoclast progenitors to the distal tibia in rats with adjuvant-induced arthritis. Lab Invest 2004;84:1092-1102.
17. Urushibara M, Takayanagi H, Koga T, et al. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum 2004;50:794-804.
18. Miyazaki M, Fujikawa Y, Takita C, et al. Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis. Clin Rheumatol 2007;26:231-239.
19. del Pozo V, Rojo M, Rubio ML, et al. Gene therapy with galectin-3 inhibits bronchial obstruction and inflammation in antigen challenged rats through interleukin-5 gene downregulation. Am J Respir Crit Care Med 2002;166:732-737.
20. López E, del Pozo V, Miguel T, et al. Inhibition of chronic airway inflammation and remodeling by galectin-3 gene therapy in a murine model. J Immunol 2006;176:1943-1950.
21. Ohshima S, Kuchen S, Seemayer CA, et al. Galectin-3 and its binding protein in rheumatoid arthritis. Arthritis Rheum 2003;48:2788-2795.
22. Ortega N, Behonick DJ, Colnot C, et al. Galectin-3 is a downstream regulator of matrix metalloproteinase-9 function during endochondral bone formation. Mol Biol Cell 2005;16:3028-3039.
23. Ho MK, Springer TA. Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies. J Immunol 1982;128:1221-1228.
24. Niida S, Amizuka N, Hara F, et al. Expression of Mac-2 antigen in the preosteoclast and osteoclast identified in the op/op mouse injected with macrophage colony-stimulating factor. J Bone Miner Res 1994;9:873-881.
25. Kuratani T, Nagata K, Kukita T, et al. Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. Histol Histopathol 1998;13:751-759.
26. Wu Z, Nagata K, Iijima T. Immunohistochemical study of NGF and its receptors in the synovial membrane of the ankle joint of adjuvant-induced arthritic rats. Histochem Cell Biol 2000;114:453-459.
27. Kukita A, Kukita T, Shin JH, et al. Induction of mononuclear precursor cells with osteoclastic phenotypes in a rat bone marrow culture system depleted of stromal cells. Biochem Biophys Res Commun 1993;196:1383-1389.
28. Kukita A, Kukita T, Hata K, et al. Heat-treated osteoblastic cell (ROS17/2.8)-conditioned medium induces the formation of osteoclast-like cells. Bone Miner 1993;23:113-127.
29. Watanabe T, Kukita T, Kukita A, et al. Direct stimulation of osteoclastogenesis by MIP-1alpha: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL. J Endocrinol 2004;180:192-201.
30. Kukita T, Kukita A, Hata K, et al. 12- O-Tetradecanoylphorbol-13-acetate inhibits osteoclast-like cell differentiation in rat bone marrow cultures by inducing macrophage polykaryons. Endocrinology 1992;130:577-584.
31. Kukita T, Wada N, Kukita A, et al. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med 2004;200:941-946.
32. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of glaectin 3. Glycoconj J 2004;19:527-535.
33. Ochieng J, Leite-Browning ML, Warfield P. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun 1998;246:788-791.
34. Stillman BN, Hsu DK, Pang M, et al. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 2006;176:778-789.
35. Magnaldo T, Fowlis D, Darmon M. Galectin-7, a marker of all types of stratified epithelia. Differentiation 1998;63:159-168.
36. Neidhart M, Zaucke F, von Knoch R, et al. Galectin-3 is induced in rheumatoid arthritis synovial fibroblasts after adhesion to cartilage oligomeric matrix protein. Ann Rheum Dis 2005;64:419-424.
37. Dasuri K, Antonovici M, Chen K, et al. The synovial proteome: analysis of fibroblast-like synoviocytes. Arthritis Res Ther 2004;6:R161-R168.
38. Pearson CM, Wood FD. Studies of arthritis and other lesions induced in rats by the injection of mycobacterial adjuvant. VII. Pathologic details of the arthritis and spondylitis. Am J Pathol 1963;42:73-95.
39. Terrier F, Hricak H, Revel D, et al. Magnetic resonance imaging and spectroscopy of the periarticular inflammatory soft-tissue changes in experimental arthritis of the rat. Invest Radiol 1985;20:813-823.
40. Shou J, Bull CM, Li L, et al. Identification of blood biomarkers of rheumatoid arthritis by transcript profiling of peripheral blood mononuclear cells from the rat collagen-induced arthritis model. Arthritis Res Ther 2006;8:R28.
41. Yasuda H, Shima N, Nakagawa N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;139:1329-1337.
42. Zhou H, Kartsogiannis V, Hu YS, et al. A novel osteoblast-derived C-type lectin that inhibits osteoclast formation. J Biol Chem 2001;276:14916-14923.
43. Zhou H, Kartsogiannis V, Quinn JM, et al. Osteoclast inhibitory lectin, a family of new osteoclast inhibitors. J Biol Chem 2002;277:48808-48815.
44. Gange CT, Quinn JM, Zhou H, et al. Characterization of sugar binding by osteoclast inhibitory lectin. J Biol Chem 2004;279:29043-29049.
45. Mey A, Leffler H, Hmama Z, et al. The animal lectin galectin-3 interacts with bacterial lipopolysaccharides via two independent sites. J Immunol 1996;156:1572-1577.
46. Janelle-Montcalm A, Boileau C, Poirier F, et al. Extracellular localization of galectin-3 has a deleterious role in joint tissues. Arthritis Res Ther 2007;9:R20.
47. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006;1760:616-635.
48. Sano H, Hsu DK, Yu L, et al. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 2000;165:2156-2164.
49. Takayanagi H, Kim S, Matsuo K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002;416:744-749.
50. Hayashi T, Kaneda T, Toyama Y, et al. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation. J Biol Chem 2002;277:27880-27886.
51. Nakamura T, Kukita T, Shobuike T, et al. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol 2005;175:5809-5816.
52. Triantaphyllopoulos KA, Williams RO, Tailor H, et al. Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum 1999;42:90-99.
53. van Holten J, Reedquist K, Sattonet-Roche P, et al. Treatment with recombinant interferon beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Rheum Ther 2004;6:R239-R249.
54. van Holten J, Smeets TJ, Blankert P, et al. Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann Rheum Dis 2005;64:1780-1782.